Corporate Distinctions

6 September 2006

Stem Cell Sciences is awarded Small/Mid-Size Company Deal of the Year by Scottish Business Insider Deals & Dealmakers for the floatation of SCS plc on the London Stock Exchange Alternative Investment Market (AIM: STEM)

29 August 2006

SCS is one of only three commercial partners in the €12 million ESTOOLS project  

25 July 2006

SCS plc in-licensing of hMADS technology for drug screening applications  

12 December 2005

Selected as a Technology Pioneer in Biotechnology by the World Economic Forum for SCS' Selection Technology which allows purification of human stem cells on the basis of any differentially expressed gene

22 November 2005

Awarded ‘Business Leader' in the field of Stem Cells in the 2005 Scientific American 50

6 October 2005

First commercial products, ESGRO Complete™ product line, licensed to Chemicon (now part of Millipore Corporation) as the first commercially available serum-free and feeder-free mouse Embryonic Stem cell medium

13 July 2005

Successful IPO and Admission to the London Stock Exchange Alternative Investment Market (AIM: STEM), raising £6.02m

18 February 2005

Australia expands into new stem cell facility and releases MEL-1 and MEL-2 human ES cell lines

31 January 2005

SCS led consortium secures £1.22 million in DTI funding to develop the use of ES cells in high-throughput assays